The treatment of chronic hepatitis C virus infection in HIV co-infection

Table 2 Studies on the treatment of chronic HCV infection in HIV/HCV co-infected patients

Study	Number patients^†	Study type	PegIFN Therapy		Patient characteristics			SVR rates
			Duration	RBV dosing mg/day	High VL %	GT1%	IDU %	Overall %	GT 1/4%	GT 2/3%
Laguno et al. 2004 [61]	52	prospective randomized controlled clinical trial	24 - 48	800 - 1200	47*	49	82	44	38	53
Nunez et al. 2007 [62]	389	prospective clinical trial	24 - 72	1000 - 1200	67*	49	90	50	35	72
Laguno et al. 2009 [63]	182	prospective randomized controlled clinical trial	48	800 - 1200	59*	45	76	44	30	66
Torriani et al. 2004 [64]	289	prospective randomized controlled clinical trial	48	800	72*	61	62	40	29^‡	62
Mira et al. 2009 [65]	542	observational cohort study	24 - 48	600 - 1500	58*	54	85	38	25	63
Rodriguez-Torres et al. 2009 [66]	410	prospective randomized controlled clinical trial	48	800 - 1200	80*	100	n.r.	-	21	-
Voigt et al. 2005 [67]	122	prospective clinical trial	24 - 48	800	45*	56	61	25	18	44
Berenguer et al. 2009 [68]	557	observational cohort study	#	#	61*	51	80	32	17	45
Carrat et al. 2004 [69]	205	prospective randomized controlled clinical trial	48	800	63*	48	80	27	17	44^$
Chung et al. 2004 [70]	66	prospective randomized controlled clinical trial	48	600 - 1000^$	83*	77	not rep.	27	14^‡	73^$

^† number of patients who received pegylated interferon;
* high viral load defined as: Chung et al. > 1 000 000 IU/ml; Rodriguez-Torres et al. > 800 000 IU/ml; Voigt et al., Laguno et al. Torriani et al. > 800 000 IU/ml; Mira et al., Laguno et al.,*Nunez et al. HCV-RNA > 600 000 IU/ml; Berenguer et al., Carrat et al. > 500 000 IU/ml;
^‡ only reported for GT1 infections;
^# reported as median 13.3 and 14.0 mg/kg body weight/day and median 8 and 11 months of treatment duration for the respective treatment group; $ Carrate et al. SVR rate reported for GT 2,3 or 5 infections: Chung et al. SVR rate reported for non-1 genotypes;
^§ dose escalating regimen, starting at 600 mg; n.r. rot reported in the abstract

ISSN: 2047-783X